OS of patients who received venetoclax-based low-intensity frontline therapy (reference, NHW patients). (A) Unadjusted Kaplan-Meier curves by race/ethnicity. (B) Predicted OS curves by race/ethnicity after adjusting for age and comorbidity. (C) Unadjusted Kaplan-Meier curves of patients without venetoclax-unfavorable mutations (TP53, KRAS, NRAS, and FLT3-ITD) by race/ethnicity. (D) Predicted OS curves of patients without venetoclax-unfavorable mutations (TP53, KRAS, NRAS, and FLT3-ITD) by race/ethnicity after adjusting for age and comorbidity.